Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 1
2009 1
2014 1
2015 2
2016 2
2017 5
2018 3
2019 2
2021 4
2022 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
Ismaila AS, Haeussler K, Czira A, Youn JH, Malmenäs M, Risebrough NA, Agarwal J, Nassim M, Sharma R, Compton C, Vogelmeier CF, Han MK, Halpin DMG. Ismaila AS, et al. Among authors: risebrough na. Adv Ther. 2022 Sep;39(9):3957-3978. doi: 10.1007/s12325-022-02231-0. Epub 2022 Jul 17. Adv Ther. 2022. PMID: 35849317 Free PMC article. Review.
Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial.
Halpin DMG, Kendall R, Shukla S, Martin A, Shah D, Midwinter D, Beeh KM, Kocks JWH, Jones PW, Compton C, Risebrough NA, Ismaila AS. Halpin DMG, et al. Among authors: risebrough na. Int J Chron Obstruct Pulmon Dis. 2022 Oct 25;17:2745-2755. doi: 10.2147/COPD.S370577. eCollection 2022. Int J Chron Obstruct Pulmon Dis. 2022. PMID: 36317185 Free PMC article. Clinical Trial.
Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial.
Ismaila AS, Risebrough N, Schroeder M, Shah D, Martin A, Goodall EC, Ndirangu K, Criner G, Dransfield M, Halpin DM, Han MK, Lomas DA. Ismaila AS, et al. Among authors: risebrough n. Int J Chron Obstruct Pulmon Dis. 2019 Nov 29;14:2681-2695. doi: 10.2147/COPD.S216072. eCollection 2019. Int J Chron Obstruct Pulmon Dis. 2019. PMID: 31819401 Free PMC article.
Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial.
Prica A, Hay AE, Crump M, Mittmann N, Shepherd LE, Meyer RM, Imrie KI, Risebrough N, Djurfeldt M, Chen BE, Cheung MC. Prica A, et al. Among authors: risebrough n. Curr Oncol. 2021 Mar 17;28(2):1256-1261. doi: 10.3390/curroncol28020119. Curr Oncol. 2021. PMID: 33802634 Free PMC article.
Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial.
Gabrio A, Gunsoy NB, Baio G, Martin A, Paly VF, Risebrough N, Halpin DMG, Singh D, Wise RA, Han MK, Martinez FJ, Criner GJ, Martin N, Lipson DA, Ismaila AS. Gabrio A, et al. Among authors: risebrough n. Int J Chron Obstruct Pulmon Dis. 2022 Jul 25;17:1633-1642. doi: 10.2147/COPD.S342244. eCollection 2022. Int J Chron Obstruct Pulmon Dis. 2022. PMID: 35915738 Free PMC article.
Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model.
Shukla S, Shah D, Martin A, Risebrough NA, Kendall R, Vogelmeier CF, Boucot I, Tombs L, Bjermer L, Jones PW, Kerwin E, Compton C, Maltais F, Lipson DA, Ismaila AS. Shukla S, et al. Among authors: risebrough na. Int J Chron Obstruct Pulmon Dis. 2021 Nov 13;16:3105-3118. doi: 10.2147/COPD.S331636. eCollection 2021. Int J Chron Obstruct Pulmon Dis. 2021. PMID: 34916789 Free PMC article.
24 results